Abstract 504P
Background
It is proved that anaplastic lymphoma kinase-rearranged non–small-cell lung cancer (ALK-rearranged NSCLC) is sensitive to ALK inhibitors while the chemotherapy resistance is unavoidable. In this study, safety and antitumor activity of the novel ALK inhibitor (ALKi) CT-707 is evaluated in Chinese patients with advanced ALK-rearranged NSCLC.
Methods
This Multi-center, open-label phase I study (NCT02695550) recruited adult patients with ALK-rearrangement (confirmed by fluorescence in situ hybridization and/or immunohistochemistry) of locally advanced/metastatic malignancies including non–small-cell lung cancer. This study consisted of a dose escalation study and a dose expansion study. CT-707 was administered orally once a day for 21 days. The Lung Cancer Center of Peking Union Medical College Hospital of Chinese Academy of Medical Sciences summarized the safety and effectiveness of the cases enrolled in this center.
Results
Thirteen patients who were treated with CT-707 from 450 to 600mg (in the dose increasing phase) were enrolled in this trial (two patients were previously treated with crizotinib). Twelve patients were diagnosed with lung adenocarcinoma and one patient was malignant pleural mesothelioma. After treatment, grade 3 diarrhea (600 mg QD) was found as dose-limiting toxicity (DLT). The most common adverse events included diarrhea (92%), elevated aspartate aminotransferase (61%), elevated alanine aminotransferase (54%), hair loss (38%), and vomiting (31%).ORR and disease control rate among patients were 10 of 13 (77%) and 11 of 13 (85%). The median progression-free survival was 13 months (95% CI:9.98-16.00).The overall survival rate of 12 months was 85%, which has not yet reached the median overall survival. Among all patients, ten patients observed partial response (PR). One patient reached a complete response (CR). However, no response of the disease was observed in patients with malignant pleural mesothelioma.
Conclusions
CT-707 is effective in Chinese patients with tumors harboring ALK rearrangements. It has reliable safety and tremendous clinical application value.
Clinical trial identification
NCT02695550; March 2016.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract